Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria for Adverse Events (CTCAE), which...
Saved in:
| Published in: | JAMA oncology Vol. 4; no. 1; p. 98 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.01.2018
|
| Subjects: | |
| ISSN: | 2374-2445, 2374-2445 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria for Adverse Events (CTCAE), which may underestimate incidence of clinically significant immune-related adverse events (AEs).
To describe detailed toxic effects and time to treatment failure of patients with melanoma treated with nivo + ipi in a prospective cohort.
A cohort of 64 adults with advanced or unresectable melanoma were examined at a single tertiary cancer and enrolled in an expanded access program of nivo + ipi conducted from December 2014 to January 2016.
Intravenous nivolumab (1 mg/kg) and ipilimumab (3 mg/kg) administered every 3 weeks for up to 4 doses, followed by nivolumab (3 mg/kg) every 2 weeks or pembrolizumab (2 mg/kg) every 3 weeks until unacceptable toxic effects, disease progression, or complete response.
Clinically significant immune-related AEs were defined as CTCAE grade 2 or higher or any immune-related AEs requiring systemic steroids. Time to treatment failure was defined as the interval between initiating therapy and the earliest of clinical progression, new locally directed or systemic treatment other than anti-programmed cell death 1 protein (anti-PD-1) monotherapy, or death.
Overall 64 adults with advanced or unresectable melanoma were enrolled (male to female ratio, 1:1; median [range] age, 56 [22-82] years); 25 patients (39%) received all 4 doses of nivo + ipi, and 31 patients (48%) received no maintenance anti-PD-1 therapy. Most who discontinued treatment (n = 31 [80%]) stopped because of toxic effects. Among those patients who were progression free at 12 weeks, time to treatment failure was similar between those who did or did not modify therapy for toxic effects. Fifty-eight patients (91%) had a clinically significant immune-related AE (median, 2/patient), and 46 patients (72%) required systemic steroids. Infliximab or mycophenolate was required in 16 patients (25%) for steroid-refractory immune-related AEs. Seven patients (11%) developed hyperglycemia, 32 patients (50%) had an emergency department visit, and 23 patients (36%) required a hospital admission related to an immune-related AE. Four of 31 patients (13%) who stopped combination therapy early for toxic effects developed a new, clinically significant immune-related AE more than 16 weeks after the last treatment.
We observed a 91% incidence of clinically significant immune-related AEs leading to frequent emergency department visits, hospitalizations, and systemic immunosuppression. Immuno-oncology trials should routinely report these metrics. Most patients do not tolerate 4 doses of nivo + ipi; however, 4 doses may not be required for clinical benefit. |
|---|---|
| AbstractList | Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria for Adverse Events (CTCAE), which may underestimate incidence of clinically significant immune-related adverse events (AEs).
To describe detailed toxic effects and time to treatment failure of patients with melanoma treated with nivo + ipi in a prospective cohort.
A cohort of 64 adults with advanced or unresectable melanoma were examined at a single tertiary cancer and enrolled in an expanded access program of nivo + ipi conducted from December 2014 to January 2016.
Intravenous nivolumab (1 mg/kg) and ipilimumab (3 mg/kg) administered every 3 weeks for up to 4 doses, followed by nivolumab (3 mg/kg) every 2 weeks or pembrolizumab (2 mg/kg) every 3 weeks until unacceptable toxic effects, disease progression, or complete response.
Clinically significant immune-related AEs were defined as CTCAE grade 2 or higher or any immune-related AEs requiring systemic steroids. Time to treatment failure was defined as the interval between initiating therapy and the earliest of clinical progression, new locally directed or systemic treatment other than anti-programmed cell death 1 protein (anti-PD-1) monotherapy, or death.
Overall 64 adults with advanced or unresectable melanoma were enrolled (male to female ratio, 1:1; median [range] age, 56 [22-82] years); 25 patients (39%) received all 4 doses of nivo + ipi, and 31 patients (48%) received no maintenance anti-PD-1 therapy. Most who discontinued treatment (n = 31 [80%]) stopped because of toxic effects. Among those patients who were progression free at 12 weeks, time to treatment failure was similar between those who did or did not modify therapy for toxic effects. Fifty-eight patients (91%) had a clinically significant immune-related AE (median, 2/patient), and 46 patients (72%) required systemic steroids. Infliximab or mycophenolate was required in 16 patients (25%) for steroid-refractory immune-related AEs. Seven patients (11%) developed hyperglycemia, 32 patients (50%) had an emergency department visit, and 23 patients (36%) required a hospital admission related to an immune-related AE. Four of 31 patients (13%) who stopped combination therapy early for toxic effects developed a new, clinically significant immune-related AE more than 16 weeks after the last treatment.
We observed a 91% incidence of clinically significant immune-related AEs leading to frequent emergency department visits, hospitalizations, and systemic immunosuppression. Immuno-oncology trials should routinely report these metrics. Most patients do not tolerate 4 doses of nivo + ipi; however, 4 doses may not be required for clinical benefit. Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria for Adverse Events (CTCAE), which may underestimate incidence of clinically significant immune-related adverse events (AEs).IMPORTANCENivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria for Adverse Events (CTCAE), which may underestimate incidence of clinically significant immune-related adverse events (AEs).To describe detailed toxic effects and time to treatment failure of patients with melanoma treated with nivo + ipi in a prospective cohort.OBJECTIVETo describe detailed toxic effects and time to treatment failure of patients with melanoma treated with nivo + ipi in a prospective cohort.A cohort of 64 adults with advanced or unresectable melanoma were examined at a single tertiary cancer and enrolled in an expanded access program of nivo + ipi conducted from December 2014 to January 2016.DESIGN, SETTING, AND PARTICIPANTSA cohort of 64 adults with advanced or unresectable melanoma were examined at a single tertiary cancer and enrolled in an expanded access program of nivo + ipi conducted from December 2014 to January 2016.Intravenous nivolumab (1 mg/kg) and ipilimumab (3 mg/kg) administered every 3 weeks for up to 4 doses, followed by nivolumab (3 mg/kg) every 2 weeks or pembrolizumab (2 mg/kg) every 3 weeks until unacceptable toxic effects, disease progression, or complete response.INTERVENTIONSIntravenous nivolumab (1 mg/kg) and ipilimumab (3 mg/kg) administered every 3 weeks for up to 4 doses, followed by nivolumab (3 mg/kg) every 2 weeks or pembrolizumab (2 mg/kg) every 3 weeks until unacceptable toxic effects, disease progression, or complete response.Clinically significant immune-related AEs were defined as CTCAE grade 2 or higher or any immune-related AEs requiring systemic steroids. Time to treatment failure was defined as the interval between initiating therapy and the earliest of clinical progression, new locally directed or systemic treatment other than anti-programmed cell death 1 protein (anti-PD-1) monotherapy, or death.MAIN OUTCOMES AND MEASURESClinically significant immune-related AEs were defined as CTCAE grade 2 or higher or any immune-related AEs requiring systemic steroids. Time to treatment failure was defined as the interval between initiating therapy and the earliest of clinical progression, new locally directed or systemic treatment other than anti-programmed cell death 1 protein (anti-PD-1) monotherapy, or death.Overall 64 adults with advanced or unresectable melanoma were enrolled (male to female ratio, 1:1; median [range] age, 56 [22-82] years); 25 patients (39%) received all 4 doses of nivo + ipi, and 31 patients (48%) received no maintenance anti-PD-1 therapy. Most who discontinued treatment (n = 31 [80%]) stopped because of toxic effects. Among those patients who were progression free at 12 weeks, time to treatment failure was similar between those who did or did not modify therapy for toxic effects. Fifty-eight patients (91%) had a clinically significant immune-related AE (median, 2/patient), and 46 patients (72%) required systemic steroids. Infliximab or mycophenolate was required in 16 patients (25%) for steroid-refractory immune-related AEs. Seven patients (11%) developed hyperglycemia, 32 patients (50%) had an emergency department visit, and 23 patients (36%) required a hospital admission related to an immune-related AE. Four of 31 patients (13%) who stopped combination therapy early for toxic effects developed a new, clinically significant immune-related AE more than 16 weeks after the last treatment.RESULTSOverall 64 adults with advanced or unresectable melanoma were enrolled (male to female ratio, 1:1; median [range] age, 56 [22-82] years); 25 patients (39%) received all 4 doses of nivo + ipi, and 31 patients (48%) received no maintenance anti-PD-1 therapy. Most who discontinued treatment (n = 31 [80%]) stopped because of toxic effects. Among those patients who were progression free at 12 weeks, time to treatment failure was similar between those who did or did not modify therapy for toxic effects. Fifty-eight patients (91%) had a clinically significant immune-related AE (median, 2/patient), and 46 patients (72%) required systemic steroids. Infliximab or mycophenolate was required in 16 patients (25%) for steroid-refractory immune-related AEs. Seven patients (11%) developed hyperglycemia, 32 patients (50%) had an emergency department visit, and 23 patients (36%) required a hospital admission related to an immune-related AE. Four of 31 patients (13%) who stopped combination therapy early for toxic effects developed a new, clinically significant immune-related AE more than 16 weeks after the last treatment.We observed a 91% incidence of clinically significant immune-related AEs leading to frequent emergency department visits, hospitalizations, and systemic immunosuppression. Immuno-oncology trials should routinely report these metrics. Most patients do not tolerate 4 doses of nivo + ipi; however, 4 doses may not be required for clinical benefit.CONCLUSIONS AND RELEVANCEWe observed a 91% incidence of clinically significant immune-related AEs leading to frequent emergency department visits, hospitalizations, and systemic immunosuppression. Immuno-oncology trials should routinely report these metrics. Most patients do not tolerate 4 doses of nivo + ipi; however, 4 doses may not be required for clinical benefit. |
| Author | Postow, Michael A Friedman, Claire F Wolchok, Jedd D Chapman, Paul B Momtaz, Parisa Shoushtari, Alexander N Panageas, Katherine S Navid-Azarbaijani, Pedram Callahan, Margaret K |
| Author_xml | – sequence: 1 givenname: Alexander N surname: Shoushtari fullname: Shoushtari, Alexander N organization: Weill Cornell Medical College, New York, New York – sequence: 2 givenname: Claire F surname: Friedman fullname: Friedman, Claire F organization: Weill Cornell Medical College, New York, New York – sequence: 3 givenname: Pedram surname: Navid-Azarbaijani fullname: Navid-Azarbaijani, Pedram organization: Weill Cornell Medical College, New York, New York – sequence: 4 givenname: Michael A surname: Postow fullname: Postow, Michael A organization: Weill Cornell Medical College, New York, New York – sequence: 5 givenname: Margaret K surname: Callahan fullname: Callahan, Margaret K organization: Weill Cornell Medical College, New York, New York – sequence: 6 givenname: Parisa surname: Momtaz fullname: Momtaz, Parisa organization: Weill Cornell Medical College, New York, New York – sequence: 7 givenname: Katherine S surname: Panageas fullname: Panageas, Katherine S organization: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 8 givenname: Jedd D surname: Wolchok fullname: Wolchok, Jedd D organization: Weill Cornell Medical College, New York, New York – sequence: 9 givenname: Paul B surname: Chapman fullname: Chapman, Paul B organization: Weill Cornell Medical College, New York, New York |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28817755$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUNFKwzAADDJxc-4LBMmjL51JmjTNo4xNB5v6UJ9LkiaS0SSzaUX_3qITfLo7uDuOuwSTEIMB4BqjJUYI3x2klzHo2C4JwnxJcoHPwIzknGaEUjb5x6dgkdIBjSnKUUHJBZiSssScMzYD9d7INHQuvMEqfjoN19Ya3ScoQwMr5w3sI6w6I3tvQg830rVDZ6CNHXxyH7EdvFTwpR0S3B5d6_yPdgHuTStD9PIKnFvZJrM44Ry8btbV6jHbPT9sV_e7TI4L-ww3kpUMaaYULRrFONfGMq6oIDZXuRYMK9ZYmbOioJLQRlMrGsKYzjGmSpM5uP3tPXbxfTCpr71L2rTjChOHVGORI8qFEOVovTlZB-VNUx8752X3Vf-dQr4Bmw5otg |
| CitedBy_id | crossref_primary_10_1097_WCO_0000000000000867 crossref_primary_10_1158_1078_0432_CCR_19_1457 crossref_primary_10_36290_far_2019_019 crossref_primary_10_1016_j_ejca_2023_01_034 crossref_primary_10_1080_14712598_2020_1699053 crossref_primary_10_1111_ijd_15163 crossref_primary_10_3389_fphar_2022_989461 crossref_primary_10_1007_s12265_020_09992_5 crossref_primary_10_1007_s40264_023_01357_6 crossref_primary_10_1186_s40425_019_0667_0 crossref_primary_10_7759_cureus_87049 crossref_primary_10_1136_jim_2021_001806 crossref_primary_10_3389_fmed_2018_00351 crossref_primary_10_1016_j_it_2019_04_002 crossref_primary_10_1016_j_semcancer_2022_05_015 crossref_primary_10_1016_j_jconrel_2021_10_013 crossref_primary_10_1080_21645515_2021_1889449 crossref_primary_10_3389_fimmu_2025_1616872 crossref_primary_10_3390_cancers15245707 crossref_primary_10_1186_s40425_018_0346_6 crossref_primary_10_1186_s40425_019_0694_x crossref_primary_10_1053_j_seminoncol_2019_10_003 crossref_primary_10_1016_j_intimp_2023_109881 crossref_primary_10_1016_j_heliyon_2024_e41597 crossref_primary_10_1097_HC9_0000000000000063 crossref_primary_10_1002_cam4_5438 crossref_primary_10_1016_j_jgo_2018_06_009 crossref_primary_10_1007_s40487_019_0096_8 crossref_primary_10_1158_1078_0432_CCR_20_3449 crossref_primary_10_1016_j_intimp_2020_106628 crossref_primary_10_1002_adtp_202000027 crossref_primary_10_1016_j_omto_2019_03_007 crossref_primary_10_1080_01658107_2019_1566385 crossref_primary_10_3390_cancers17111747 crossref_primary_10_3389_fimmu_2022_860421 crossref_primary_10_1016_j_jid_2021_06_026 crossref_primary_10_1038_s41416_024_02887_1 crossref_primary_10_1016_j_jconrel_2018_06_035 crossref_primary_10_1016_j_critrevonc_2021_103354 crossref_primary_10_1002_cncr_32506 crossref_primary_10_1002_cam4_4076 crossref_primary_10_2174_0109298673283943240227104122 crossref_primary_10_1002_cncr_34004 crossref_primary_10_1097_MED_0000000000000418 crossref_primary_10_1038_s41598_018_37883_y crossref_primary_10_1016_j_clon_2021_06_009 crossref_primary_10_1016_j_phymed_2023_154765 crossref_primary_10_1002_cam4_4405 crossref_primary_10_1016_j_ejca_2021_04_045 crossref_primary_10_1038_s41568_022_00503_z crossref_primary_10_1002_adtp_202000055 crossref_primary_10_1016_j_cej_2024_153131 crossref_primary_10_1002_cncr_31889 crossref_primary_10_3390_cancers14102460 crossref_primary_10_1136_annrheumdis_2019_216510 crossref_primary_10_1200_JCO_18_00145 crossref_primary_10_1016_j_cpccr_2020_100044 crossref_primary_10_1002_cam4_70011 crossref_primary_10_3390_cancers14215267 crossref_primary_10_1007_s00345_021_03632_6 crossref_primary_10_3389_fonc_2022_1026978 crossref_primary_10_1016_j_rdc_2020_04_003 crossref_primary_10_1158_1078_0432_CCR_20_4189 crossref_primary_10_1002_art_40745 crossref_primary_10_3390_cancers13122931 crossref_primary_10_1212_CON_0000000000000873 crossref_primary_10_12998_wjcc_v8_i18_4100 crossref_primary_10_1093_oncolo_oyad097 crossref_primary_10_1016_j_toxlet_2024_11_007 crossref_primary_10_1080_14740338_2020_1757068 crossref_primary_10_1016_j_ijrobp_2020_07_2326 crossref_primary_10_1007_s00520_020_05710_8 crossref_primary_10_2217_imt_2021_0082 crossref_primary_10_1371_journal_pone_0255716 crossref_primary_10_3390_vaccines6040079 crossref_primary_10_1186_s12967_023_04784_2 crossref_primary_10_1007_s13671_023_00415_7 crossref_primary_10_1080_09273948_2020_1773867 crossref_primary_10_3390_cancers13215510 crossref_primary_10_3390_cimb47030184 crossref_primary_10_3390_ijms24032769 crossref_primary_10_1136_jitc_2022_005635 crossref_primary_10_1002_jso_26229 crossref_primary_10_1007_s00262_019_02321_z crossref_primary_10_1200_JCO_19_00508 crossref_primary_10_3390_cancers17121992 crossref_primary_10_1016_j_gore_2025_101955 crossref_primary_10_1200_JCO_18_02141 crossref_primary_10_1016_j_ccc_2020_08_003 crossref_primary_10_1159_000487082 crossref_primary_10_3389_fmed_2022_1014257 crossref_primary_10_1186_s40425_018_0426_7 crossref_primary_10_3322_caac_21596 crossref_primary_10_1007_s00345_021_03716_3 crossref_primary_10_1016_j_jaad_2020_03_132 crossref_primary_10_1186_s13046_022_02568_y crossref_primary_10_1634_theoncologist_2020_0373 crossref_primary_10_1200_EDBK_280539 crossref_primary_10_1136_jitc_2019_000331 crossref_primary_10_3389_fonc_2022_836859 crossref_primary_10_1002_cncr_32542 crossref_primary_10_1007_s40259_020_00428_9 crossref_primary_10_1038_s41571_020_0352_8 crossref_primary_10_1136_jitc_2024_009061 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1001/jamaoncol.2017.2391 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2374-2445 |
| ExternalDocumentID | 28817755 |
| Genre | Clinical Trial Journal Article |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | 0R~ 53G ABBLC ABJNI ABPMR ACGFS ADBBV ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BRYMA C45 CGR CUY CVF EBS ECM EIF EJD H13 NPM NYF OGEVE OVD RAJ TEORI 7X8 |
| ID | FETCH-LOGICAL-a445t-1da5850c5bb46db577cef57b492f3b3c951b5dfa35664a24dc4f9d255c3114bc2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 127 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000422795300019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2374-2445 |
| IngestDate | Fri Jul 11 08:15:36 EDT 2025 Thu Jan 02 22:54:07 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a445t-1da5850c5bb46db577cef57b492f3b3c951b5dfa35664a24dc4f9d255c3114bc2 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 28817755 |
| PQID | 1930479998 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1930479998 pubmed_primary_28817755 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-01-01 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – month: 01 year: 2018 text: 2018-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JAMA oncology |
| PublicationTitleAlternate | JAMA Oncol |
| PublicationYear | 2018 |
| SSID | ssj0001470642 |
| Score | 2.4738317 |
| Snippet | Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 98 |
| SubjectTerms | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Compassionate Use Trials Disease Progression Disease-Free Survival Drug-Related Side Effects and Adverse Reactions - epidemiology Female Humans Incidence Ipilimumab - administration & dosage Ipilimumab - adverse effects Male Melanoma - drug therapy Melanoma - epidemiology Melanoma - pathology Middle Aged Nivolumab - administration & dosage Nivolumab - adverse effects Prospective Studies Skin Neoplasms - drug therapy Skin Neoplasms - epidemiology Skin Neoplasms - pathology Time Factors Treatment Failure Young Adult |
| Title | Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28817755 https://www.proquest.com/docview/1930479998 |
| Volume | 4 |
| WOSCitedRecordID | wos000422795300019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC6arK72eQkIhY9JPRQobewr0CgTappxZ_v7CalIAiCl0AOgTD5MvPNN7MzCN04-R6wYUmoCk1YpBkBVi9JohMIMDELAs38sgmRZfF4nAw7wa3p2iqXPtE7alNrp5HfAdFw09AhO3iYvRO3NcpVV7sVGuuoR4HKOFSLcbzSWJhw_NrvlxOMQCTjPwYP1RWY2zV4iduQJsHvNNOHm8Huf190D-10RBM_tsjYR2u2OkBbaVdKP0R56tVBiFx4VH-VGrdzjBssK4PdwRA8r_Fo2YaOB7J0DewYOC7OSu_TpMLDyaLBr7NyUk79fVnh1E5kVU_lEXobPI-eXki3bYFIsMucBEZC6nCvuVIsMooLoW3BhWJJWFBFNVAxxU0hKRBAJkNmNCsSAxmJppBTKR0eo42qruwpwpRaERpmaJTEEO8ixWkRhSJy5E_YWPbR9dJ0OaDZlShkZetFk6-M10cnrf3zWTt2Iw_jOBCC87M_PH2OtuGjxq1WcoF6BfzL9hJt6s952XxceZjANRum31E7xlg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Measuring+Toxic+Effects+and+Time+to+Treatment+Failure+for+Nivolumab+Plus+Ipilimumab+in+Melanoma&rft.jtitle=JAMA+oncology&rft.au=Shoushtari%2C+Alexander+N&rft.au=Friedman%2C+Claire+F&rft.au=Navid-Azarbaijani%2C+Pedram&rft.au=Postow%2C+Michael+A&rft.date=2018-01-01&rft.issn=2374-2445&rft.eissn=2374-2445&rft.volume=4&rft.issue=1&rft.spage=98&rft_id=info:doi/10.1001%2Fjamaoncol.2017.2391&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2374-2445&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2374-2445&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2374-2445&client=summon |